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T
he translation of cardioprotection to clinical practice has been disappointing so far.
1,2 Lefer and Marban 3 have even questioned whether cardioprotection is still alive because there is at present, after >30 years of intense investigation, 4 no phase III trial with improved clinical outcome after a cardioprotective intervention.
However, this provocative question appears exaggerated. In fact, there are a number of promising clinical proof-of-concept trials on cardioprotection with surrogate end points, notably infarct size by biomarkers and imaging, 5 and the existing neutral or negative clinical outcome trials have major conceptual and methodological problems. 6 The biggest problem in the field of cardioprotection, however, is our limited mechanistic understanding, despite literally thousands of experimental studies on its molecular signaling mechanisms. 7 Almost 10 years ago, I wrote an editorial for Circulation on cardioprotection that focused on nitric oxide, protein kinases, and mitochondria. 8 It seems that we have not progressed much further in our understanding of cardioprotection but only in detail. Nitric oxide activates guanylate cyclase to increase cyclic guanosine monophosphate formation as well as nitros(yl)ates proteins, which are involved in cardioprotective signaling. Nitrite/nitric oxide also participates in the humoral signal transfer of remote ischemic conditioning. 7, 9 Clinical trials with intravenous or intracoronary nitrite in patients with reperfused acute myocardial infarction have been neutral or borderline in terms of infarct size reduction, but a recent trial on nitrates combined with the reactive oxygen species scavenger N-acetylcysteine demonstrated an infarct size reduction in patients with reperfused acute myocardial infarction. 10 The neutral trial on protein kinase C delta inhibition has dampened the enthusiasm about the involvement of protein kinase C in cardioprotection, but other protein kinase C isoforms and protein kinases have not been thoroughly investigated. 2 Mitochondria as potential end effectors of cardioprotection are still at the center of attention. After a promising proof-of-concept trial, larger phase III trials on cyclosporine A to inhibit mitochondrial permeability transition pore opening in patients with reperfused acute myocardial infarction have been disappointing, but the role of pharmacokinetics in these neutral trials is not clear, given the lack of adequate phase II dosing and timing studies. Other trials with other mitochondrial targets have also been neutral or negative, 11 but their underlying mechanistic rationale was less clear than that for cyclosporine A.
The present study by Frankenreiter et al 12 supports the notion of a nitric oxide-protein kinases-mitochondria axis as a backbone of cardioprotective signaling with novel and more detailed data. Using a combination of transgenic, pharmacological, and electrophysiological approaches, the big conductance potassium channels in cardiomyocyte mitochondria were identified as a target of the nitric oxide-cyclic guanosine monophosphateprotein kinase G cardioprotective signaling pathway and an important signaling element that impacted the formation of reactive oxygen species and ultimately cardiomyocyte viability and left ventricular remodeling in mice with myocardial infarction. More specifically, mice with a cardiomyocyte-specific knockout of big conductance potassium channels had a larger infarct size after 30-minute coronary occlusion and 120-minute reperfusion and were less protected by ischemic pre-and postconditioning maneuvers, guanylate cyclase stimulators/ activators, and phosphodiesterase 5 inhibitors. In a chronic infarct model, mice with cardiomyocyte-specific knockout of big conductance potassium channels had more fibrosis and lower left ventricular function. Mechanistically, the activation of big conductance potassium channels in the inner mitochondrial membrane by cyclic guanosine monophosphate and protein kinase G was identified by patch clamping. As a consequence of activating the big conductance potassium channels, the formation of reactive oxygen species was reduced, and the cardioprotective protein kinase B (Akt) and extracellular signal-regulated kinase were activated. Collectively, novel mechanistic details on the nitric oxide-protein kinases-mitochondria axis of cardioprotective signaling are provided, notably the involvement of mitochondrial big conductance potassium channels.
However, many important questions about the role and position of cyclic guanosine monophosphate, protein kinase G, and mitochondrial big conductance potassium channels in the signaling pathways of cardioprotection remain. An interaction of mitochondrial potassium channels with reactive oxygen species formation is not unique for big conductance potassium channels but has been previously reported for ATP-dependent potassium channels and connexin 43. 7 The biochemical and subcellular source of reactive oxygen species, their chemical identity, and their targets remain to be identified. It is important to note that the threshold between low concentrations of reactive oxygen species, which are believed to be beneficial signaling molecules and may activate protein kinases, and high/detrimental concentrations of reactive oxygen species, which damage DNA, lipids, and proteins, must be identified. 9 The relative role and position in the cardioprotective signaling of Akt and extracellular signal-regulated kinase, which were shown to be phosphorylated to a greater extent in the present study when big conductance potassium channels were activated, remain to be clarified, and the causal involvement of both Akt and extracellular signalregulated kinase appears to be species-specific and limited to rodents. 7 Finally, the identity and importance of the mitochondrial permeability transition pore, which the authors propose as the ultimate gatekeeper of cardioprotection, remain to be identified. 6, 7 More fundamental questions also remain. What is the causal and quantitative relationship between the different modes of cell death? 13 In the context of the present study, what does a terminal deoxynucleotidyl transferase-biotin nick end labeling-positive, presumably apoptotic cell in triphenyl tetrazolium chloridenegative, presumably necrotic tissue mean? From which mode of cell death during ischemia and reperfusion does a cardioprotective intervention rescue? Is cell death by autophagy cardioprotective?
2 Does a cardioprotective intervention also protect the coronary circulation, and what is the role of the nitric oxide-protein kinases-mitochondria signaling axis in vascular protection?
14 Does a cardioprotective intervention only extend the time window for reperfusion to salvage myocardium or does it also protect nonreperfused myocardium from remodeling?
In conclusion, we must move forward by further elucidating the details of cardioprotective signaling in mechanistic studies such as the present one, translating mechanistic findings from rodent models to large animal models with comorbidities and comedications and to early proof-of-concept clinical trials, and designing and conducting better large clinical outcome trials. I am convinced we will then eventually recruit the potential of cardioprotection for clinical practice.
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